Liver Diseases Therapeutics Market

Global Liver Diseases Therapeutics Market Size (2024 to 2029)

The global liver diseases therapeutics market size is expected to be valued at USD 18.35 Billion in 2024 and USD 31.34 Billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029. 

Liver diseases are the most common pathological problem faced by people worldwide. Liver diseases affect more than 1.5 billion people worldwide. Many types of hepatic cells are involved in initiating and propagating acute and chronic liver diseases. Understanding the molecular mechanisms of liver diseases leads to the discovery of new therapeutic interventions. Liver diseases include hepatitis caused by viruses, diseases caused by drugs, poisons, or alcohol, liver cancer, and inherited diseases. The common symptoms observed are swelling of the abdomen and legs, bruising, color change in urine and stool, and yellowing of skin or eyes. 

Global Liver Diseases Therapeutics Market Drivers:

The growing prevalence of liver diseases across the world is demanding therapeutic interventions for treating these diseases. The increasing adoption of a sedentary lifestyle among people with no physical exercise and an unbalanced diet is leading to a rise in liver diseases. The growing older population is witnessing the prevalence of liver diseases like hepatitis, non-alcoholic fatty liver, and autoimmune diseases, which is raising the demand for treatment therapeutics and propelling the global market growth. The increasing alcohol consumption worldwide by people is one of the primary factors inducing liver diseases. According to a Journal of Hepatology article in 2022, a temporary increase in alcohol consumption can significantly increase the risk of long-term illness and death from alcohol liver disease. All these factors drive the growth of the global liver disease therapeutics market by raising the adoption of therapeutics for treating liver diseases. According to the American Association for Study of Liver Diseases publication in 2021, the most causes of prevalent diseases are non-alcoholic liver disease (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (2%). The growing prevalence of cancer, which includes liver cancer, will enhance the demand for liver disease therapeutics, which will fuel the growth rate of the global market. 

An increasing number of initiatives from the governments of several countries and public organizations are focusing primarily on raising awareness among people across the world, which is contributing to the growth of the global liver diseases therapeutics market. For Instance, In January 2023, the International Liver Transplantation Society, the International Living Donor Liver Transplantation Study Group, and the Liver Transplant Society of India held the first Asia's largest consensus conference on how to care for patients who get tiny liver grafts in India. All these organizations promote awareness of liver-related diseases and support the research and development for preventing, treating, and curing liver diseases, these factors are boosting the growth of the global liver disease therapeutics market.

The increasing research and development activities for developing effective and safe therapeutics in treating liver diseases will provide lucrative market growth during the forecast period. The growing pharmaceutical industry is expected to boost the development of innovative therapeutics with minimal effects, increasing liver disease therapeutics demand and impacting the global market revenue in the upcoming years. The growing adoption of technology in the healthcare industry search activities supports the supports by providing advanced solutions that enhance those therapeutics for treating liver diseases. 

Global Liver Diseases Therapeutics Market Restraints:

The primary factor restraining the liver disease therapeutics market is the high cost of the treatment drugs or therapies. As the market players are using extensive technologies in manufacturing, the costs of the active ingredient and excipients are increasing the final product's overall cost, which is difficult for many people in areas with low or middle-income levels. These factors are influencing people by impeding the adoption of therapeutics for the treatment of liver diseases. The presence of side effects observed by the consumption of drugs, especially used in chemotherapy, is expected to hinder the global liver disease therapeutics market growth.

The stringent regulations for the approval of therapeutic drugs by the regulatory authorities are challenging for the manufacturers as it is complex, time-consuming, and expensive. The presence of alternative therapies for liver disease treatment may limit the adoption of therapeutic therapies, which hamper the global market revenue. 

Impact of COVID-19 on the liver disease therapeutics market:

The Pandemic had a mixed impact on the liver disease therapeutics market as due to the lockdown, production and manufacturing were delayed, there were disruptions in the distribution channels, and the lockdown regulations affected the import and export of therapeutic drugs. The main focus is on treating COVID-19 patients where other non-emergency patients are avoided to help reduce the spread of the COVID-19 virus. However, various studies showed that certain liver diseases are related to immune system problems, which increased people's awareness of taking treatment at the correct time. 

REPORT COVERAGE:

This market research report on the liver diseases therapeutics market has been segmented and sub-segmented based on the following categories.

Global Liver Diseases Therapeutics Market - By Treatment:

• Antiviral Drugs
• Immunosuppressants
• Vaccines
• Immunoglobulins
• Corticosteroids
• Targeted Therapy
• Chemotherapy

The antiviral drugs segment witnessed the largest market share in the global liver diseases therapeutics market revenue in 2023. Antiviral drugs are most widely used to treat hepatitis as these drugs reduce the virus present in the body, which decreases the risk of cirrhosis and hepatocellular cancer. The growing incidence of viral liver diseases and the effective antiviral therapeutics are primarily contributing to the segment growth. Chronic hepatitis infection is one of the significant public concerns across the globe as it leads to cirrhosis and hepatocellular cancer, which is increasing the adoption of therapies or drugs to treat the disease. These conditions are expected to enhance the adoption of therapeutic drugs in the upcoming years, where the segment will witness significant growth during the forecast period. 

The Immunosuppressants segment is expected to have prominent market growth after the antivirals in the global market with a steady CAGR during the forecast period. As in most cases, liver transplantation is a wide option; immunosuppressants are being adopted to reduce the fight against the transplanted organ. 

Global Liver Diseases Therapeutics Market - By Disease:

• Hepatitis 
• Autoimmune Diseases
• Non-alcoholic fatty liver disease (NAFLD)
• Cancer 
• Genetic disorders
• Others 

The hepatitis segment dominated the global liver disease therapeutics market with a significant market share in 2023. The inflammation in the liver leads to hepatitis, which is caused by a virus. Hepatitis is classified into three categories based on the properties of the disease. The increasing adoption of a sedentary lifestyle, including an unhealthy diet and consumption of alcohol, is primarily raising the cases of hepatitis worldwide. Hepatitis is majorly observed in low- and middle-income countries due to low access to clean water and food.

The cancer segment is expected to have a significant CAGR during the forecast period due to the rising prevalence of liver cancer worldwide. The increasing cases of chronic hepatitis infections, cirrhosis, and other inherited diseases enhance the cause of liver cancer. 

Global Liver Diseases Therapeutics Market - By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The hospital pharmacies segment held the largest market share in the global market revenue due to the presence of skilled healthcare professionals. The growing government funding and increasing collaborations between hospitals and pharmaceutical companies are enhancing the adoption of hospital pharmacies. The development of healthcare infrastructure and expenditure is influencing hospital pharmacies. 

The online pharmacies segment is projected to have the fastest growth with a significant CAGR due to the wide adoption of digital platforms among people worldwide. The Pandemic has influenced people to adopt digital technology, which is convenient and straightforward.

Global Liver Diseases Therapeutics Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

The North American region dominated the global liver disease therapeutics market due to the increasing prevalence of liver diseases, which is being triggered by the excessive consumption of alcohol, an unbalanced diet, and a sedentary lifestyle. According to the Centers for Disease Control and Prevention, in January 2023, nearly 4.5 million people were diagnosed with liver disease in the United States. The same source also stated that alcohol consumption is high in the region, which is increasing the chances of liver disease in people. These factors state that over the next few years, the North American region will witness significant growth during the forecast period due to the advanced healthcare system and the presence of top pharmaceutical companies with prominent research centers working on drug design and discovery. All these factors are enhancing the region's global market revenue growth. 

The Asia Pacific region is estimated to witness the fastest growth in the forecast period, with a prominent CAGR due to growing research and development activities. The presence of prominent branches of the major market players and pharmaceutical companies propels regional market growth. 

KEY MARKET PLAYERS:

Abbott Laboratories, Gilead Sciences, Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Zydus Pharmaceuticals Inc., Bristol Myers Squibb, Merck & Co. Inc., MAX BioPharma, Takeda Pharmaceuticals are some of the key market players in the liver diseases therapeutics market.

RECENT MARKET DEVELOPMENTS:

• In January 2023, Takeda and Arrowhead Pharmaceuticals Inc. announced their results from Phase 2 SEQUONIA clinical study of investigational Fazirsiran in the treatment of liver diseases associated with alpha-1 antitrypsin deficiency. 
• In January 2022, Merck received approval for its drug Keytruda, which reduced the risk of death by 21% over placebo in hepatocellular carcinoma patients in Asia.
• In June 2022, Gilead Sciences, Inc., a research-based pharmaceutical company focused on discovering, developing, and commercializing innovative medicines, stated that more than 80 abstracts are there to present at the International Liver Congress. 
• In March 2023, F. Hoffmann-La Roche Ltd, a biotechnology company that develops drugs and diagnostics for treating major diseases, announced its collaboration with Eli Lilly and Company, a pharmaceutical company. This collaboration supports the development of Roche's Elecsys Chronic Liver Diseases Therapeutics.